RxDoctor Payments DataLook up a doctor →

Mandar Jagtap, DO

Cardiovascular Disease · Corinth, MSNPI 1255560918

Payments from drug & device makers

$20,050in general payments, 2019–2025

Across 535 payments — averaging $37.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$4K
  • Medtronic$3K
  • Boston Scientific$3K
  • Johnson & Johnson$1K
  • AstraZeneca$960
  • Abbott$946
  • plus $8K from 39 others

What the payments were for

  • Travel & lodging$4,42622%
  • Food & beverage$15,32976%
  • Education$2961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,050 in reported general payments places this provider in the 80th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,842,342
Medicare patients
2,956
Services billed
11,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban429$322,547
XareltoRivaroxaban329$247,549
EntrestoSacubitril/Valsartan161$118,544
Repatha SureclickEvolocumab47$34,491
FarxigaDapagliflozin Propanediol53$33,785
BrilintaTicagrelor64$30,804
JardianceEmpagliflozin32$25,246
Ranolazine ErRanolazine310$17,824
Metoprolol Succinate1,557$16,079
MounjaroTirzepatide12$14,166
Nifedipine ErNifedipine595$9,681
Flecainide Acetate290$8,117
Praluent PenAlirocumab14$6,448
Potassium Chloride431$5,276
VascepaIcosapent Ethyl15$5,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$581$322,547429 claims
Johnson & JohnsonXarelto$1,022$247,549329 claims
NovartisEntresto$659$118,544161 claims
AstraZenecaFarxiga, Brilinta$960$64,589117 claims
Boehringer IngelheimJardiance$392$25,24632 claims
Kowa Pharmaceuticals America, Inc.Livalo$17$1,31811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Corinth

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →